AstraZeneca’s aldosterone synthase inhibitor, Baxdrostat, succeeded in its Phase III BaxHTN trial, meeting primary and secondary endpoints in patients with uncontrolled or treatment-resistant hypertension. The drug, acquired through CinCor Pharma’s buyout, offers a novel mechanism for blood pressure control. Positive data reinforce AstraZeneca’s strategic investment and position Baxdrostat for regulatory filing and potential market approval, challenging existing hypertension treatments.